Fig 1: Interleukin 17A detection in the buffer: (a) Plasmonic spectra obtained via different IL-17A concentrations in the buffer from 0.1 aM to 1000 aM, and inset shows an enlargement of the resonance peak; (b) Dose–response curve: wavelength shift with respect to the blank (absolute module) as a function of IL-17A concentration in a semilog scale, together with the Langmuir fitting of the experimental values and error bars (maximum measured standard deviation).
Fig 2: Selectivity test: pollen-based nanoplasmonic biosensor response to IL-1β and IL-18 at 100 aM and to IL-17A at 5 aM. One-way ANOVA # p < 0.05 vs. IL-1β and * p < 0.05 vs. IL-18.
Fig 3: Immunomodulatory and immunosuppressive properties of hUCB-MSCs. (a) Identification of hUCB-MSCs by flow cytometry to determine surface expression of CD73, CD90, CD105, and CD44. (b) Non-differentiated hUCB-MSCs. The differentiation potential of hUCB-MSCs into osteoblasts and adipocytes. Scale bar: 50 μm. (c) ELISA analysis of PGE2, TGF-β1, and IL-6 secretion in cell culture supernatants demonstrated the immunomodulatory and immunosuppressive properties of hUCB-MSCs following preconditioning with psoriasis-associated proinflammatory cytokines TNF-α, IL-17A, and IL-22. (d) The results of real-time PCR analysis of immunosuppressive gene expression in hUCB-MSCs preconditioned with cytokines. * p < 0.05; ** p < 0.01; *** p < 0.001.
Fig 4: Plasmonic spectra achieved at different IL-17A concentrations (ranging from 0.1 fM to 104 fM) in PBS.
Fig 5: Plasmonic spectra achieved for IL-17A (500 aM) at different incubation times on the LSPR-BC biosensor. The spectra are acquired every minute for a total of 5 min.
Supplier Page from Abcam for Recombinant human IL-17A protein (Active)